Enliven Therapeutics shareholders approved authorized common stock increase to 200 million shares at annual meeting

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVN

0.00

  • Enliven Therapeutics held its annual shareholder meeting on June 9, 2026.
  • Shareholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
  • Investors backed an increase in authorized common stock to 200 million shares from 100 million.
  • The charter amendment was executed through a filed certificate of amendment, effective June 9, 2026.
  • Shareholders supported holding future advisory votes on executive pay every year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-264085), on June 10, 2026, and is solely responsible for the information contained therein.